Equillium, Inc. (EQ) compared with its closest peers (INDP, OKUR, NRXP, ASRT, UNCY). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $170.55M | -0.1 |
| OnKure Therapeutics, Inc. (OKUR) | $158.95M | -0.7 |
| NRx Pharmaceuticals, Inc. (NRXP) | $152.83M | -2.0 |
| Assertio Holdings, Inc. (ASRT) | $151.83M | -1.9 |
| Unicycive Therapeutics, Inc. (UNCY) | $150.32M | -3.4 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $148.57M | -4.5 |
| Spruce Biosciences, Inc. (SPRB) | $141.05M | -1.7 |
| TuHURA Biosciences, Inc. (HURA) | $127.13M | -1.2 |
| Anixa Biosciences, Inc. (ANIX) | $126.06M | -12.1 |
| Genelux Corporation (GNLX) | $122.61M | -5.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
EQ overview · EQ earnings · EQ financials · EQ KPIs · EQ investor relations · EQ ownership · EQ filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.